Corvus Pharmaceuticals, Inc. · NASDAQ:CRVS

Corvus Pharmaceuticals — Technical Presentation (2017)

15 slides from Corvus Pharmaceuticals's technical presentation, 2017

  1. Slide 1: Clinical Activity of A2aR Inhibitor CPI-444 Associated with Tumor Expression of Adenosine Pathway Genes

    Clinical Ac)vity of Adenosine A2A Receptor (A2aR) Inhibitor CPI-444 is Associated with Tumor Expression of Adenosine Pathway Genes and Tumor Immune Modula)on Drew Hotson1, John Powderly2, Leisha Emens3, Patrick Forde3, Matthew Hellmann4, Lawrence Fong5, Ben Markman6, Brett Hughes7, Jonathan Goldman8

  2. Slide 2: Disclosures

    Capitalized title Disclosures A2aR Consultancy 7 Hills, Actym, Amgen, Array, AstraZeneca, BeneVir, Bristol-Myers Squibb, Castle, CheckMate, EMD Serono, Gilead, Janssen, Novartis, Merck Clinical Trial Support to Institution AbbVie, Boston Biomedical, Bristol-Myers Squibb, Celldex, Corvus, Delcath, Fi

  3. Slide 3: Background

    Background • An2-PD-(L)1 an2bodies are approved for treatment of Adenosine in the tumor microenvironment2,3 several cancers but a small propor2on of pa2ents benefit T Cell CPI-444 • Mechanisms of an2-PD-(L)1 resistance are not well Adenosine understood and no agents are approved to overcome AMP resis

  4. Slide 4: Phase 1/1b Clinical Study with Oral Drug CPI-444

    Phase 1/1b Clinical Study with Oral Drug CPI-444 Cohort Expansion CPI-444 Dose 100 mg BID 28 days RCC Monotherapy Selec@on NSCLC Melanoma TNBC CPI-444 with Cohort Expansion Others atezolizumab Dose 100 mg BID 28 days + (an@-PD-L1) Selec@on 840 mg atezolizumab Q2W Eligibility • Prior an2-PD-(L)1 allo

  5. Slide 5: Prior Anti-PD-(L)1 Treatment Increases A2AR, CD73 and CD39

    Prior An2-PD-(L)1 Treatment Increases A2AR, CD73 and CD39 Adenosine pathway is a poten)al mechanism of resistance Exposure toA2AR CD73 an2-PD-(L)1 therapy (> 3 months) CD39 increases A2AR, CD73, and CD39 expression p=0.1 p=0.002 p=0.002 1000 10000 1000 p=0.002 p=0.01 p=0.003 A2AR Expression CD73 Exp

  6. Slide 6: Adenosine Pathway Expression is Higher in RCC and NSCLC Pre-Treatment Biopsies

    Adenosine Pathway Expression is Higher in RCC and NSCLC Pre- Treatment Biopsies A2AR CD73 CD39 p < 0.0001 p = 0.03 p < 0.0001 1000 10000 1000 p = 0.05 p < 0.0001 p = 0.0002 A2AR Expression CD73 Expression CD39 Expression 1000 100 100 100 n=19 n=33 n=49 n=19 n=33 n=49 n=19 n=33 n=49 10 10 10 C LC er

  7. Slide 7: Patient characteristics

    Renal Cell Cohorts Expanded Pa)ent characteris)cs Renal Cell Cancer (N=51) Prior an@-PD-(L)1 exposure Naïve 16 (31%) Resistant/Refractory 35 (69%) PD-L1 Nega@ve (archival) * 91% Median @me since IO agent, months (range) 1.6 (1 – 71) 50 (98%) Clear cell Histology 1 (2%) Papillary Median age, years (r

  8. Slide 8: CPI-444 Anti-Tumor Activity in Renal Cell Cancer

    CPI-444 An2-Tumor Ac2vity in Renal Cell Cancer Responses with single agent and combina)on Partial Responses in RCC Single Agent Combination Single agent CPI-444 (atezolizumab-refractory) Combination CPI-444 + atezolizumab Resistant to prior IO Refractory to prior IO Naïve to prior IO Data cutoff 10/

  9. Slide 9: Renal Cell Cancer

    Renal Cell Cancer Response rate and disease control rate in evaluable pa)ents Treatment Objec@ve Response Disease Control Rate Rate CPI-444 2*/14 (14%) 4/14 (29%) CPI-444 + atezolizumab *1 unconfirmed 2/16 (13%) 11/16 (69%) CPI-444 CPI-444 + atezolizumab % change from baseline % change from baseline

  10. Slide 10: Treatment-Related Adverse Events

    Treatment-Related Adverse Events Adverse Events (Gr1/2) > 5% Frequency (n=210) CPI-444/Atezo CPI-444 (%) (%) Grade > 3 Serious Adverse Events Fa@gue 21 29 CPI-444 (n=1) Nausea 12 14 • Gr 3 nausea/vomiting/diarrhea Pruritus 11 10 CPI-444/Atezolizumab (n=5) Pyrexia 5 9 • Gr 3 immune related hepatitis,

  11. Slide 11: Screening A2AR and CD73 Associated with Response

    Screening A2AR and CD73 Associated with Response Double posi)ve A2AR, CD73 may be predic)ve A2AR CD73 A2AR+/CD73+ 150 150 Tumor Response (Best % Change) p=0.01 p=0.09 p=0.0006 Tumor Resonse (Best % Change) Tumor Resonse (Best % Change) Progression 100 100 50 50 0 0 Partial Regression Responses✝ -50

  12. Slide 12: Screening A2AR, CD73 Associated with Disease Control Rate

    Screening A2AR, CD73 Associated with Disease Control Rate Double posi)ve A2AR, CD73 may be predic)ve Disease Control Rate (all indica@ons; biomarker assessable) Nega@ve Posi@ve A2AR 4/39 (10%) 10/34 (29%) CD73 2/22 (9%) 12/51 (24%) A2AR + CD73 4/49 (8%) 10/24 (42%)* (Double Posi@ve) *p=0.0007

  13. Slide 13: In CD73+ Tumors, CPI-444 Induces T Cell Activation Markers

    In CD73+ Tumors, Single Agent CPI-444 Induces Expression of T cell Ac2va2on Markers in Post-Dose Biopsies CD8 infiltration IHC Infiltration PD-L1 IHC single-agent Inflammation Sheet 3 IFNγ Induction Effector Checkpoints single-agent fold CD73 Q1 vs delta CD73 Q1 vs Q2 to Q2 to 4 CD8 (IHC) 4 PD-L1 (IH

  14. Slide 14: Summary

    Summary • Tumor expression of A2AR, CD73 and CD39 are increased in pa2ents that are resistant to prior treatment with an2-PD-(L)1 • RCC and NSCLC have high tumor expression of adenosine pathway genes A2AR, CD73 and CD39 • CPI-444 has an2-tumor ac2vity in RCC – Reponses seen in an2-PD-(L)1 resistant/

  15. Slide 15: Acknowledgements

    Acknowledgements Patients and their Families Clinical Investigators and their staff Colleagues at Corvus

Corvus Pharmaceuticals — Technical Presentation (2017) on 6ix